Joe Shenton
Co-Founder and Managing Partner at Permanent Capital Partners
Chicago, United States
Joe Shenton, Co-Founder and Managing Partner at Permanent Capital Partners is an active investor based in Chicago, United States. This profile covers what Joe Shenton backs, at which stage, and how founders can reach out in 2026.
- Investor type
- VC
- Stages
- SeedSeries A
- Invests in
- SaaS & Enterprise
- Location
- Chicago, United States
- Typical check
- $625K
How to reach Joe Shenton
Angels and operators like Joe Shenton reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Joe Shenton
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
What does Joe Shenton invest in?
Joe Shenton invests in SaaS & Enterprise, typically at Seed and Series A. Match your sector and stage, then reach out with a personalized pitch.
What stage does Joe Shenton invest at?
Joe Shenton typically invests at Seed and Series A. Lead with traction that fits the stage when you reach out.
What is Joe Shenton's typical check size?
Joe Shenton typically writes checks around $625K. Use it as a signal for whether your raise fits their stage.
How do I contact Joe Shenton?
Unlock Joe Shenton's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.